Published in Infect Immun on December 01, 1997
Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC). PLoS One (2015) 1.43
Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities. Infect Immun (2005) 1.24
Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines (2007) 1.17
Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun (2005) 1.15
Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology (1998) 1.11
Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun (2000) 1.09
Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells. Infect Immun (2005) 1.02
Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect Immun (2000) 0.98
Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its vlosely related homologue, the B subunit of cholera toxin. Infect Immun (2001) 0.97
Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. Infect Immun (2006) 0.96
The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun (2012) 0.93
Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I). Clin Vaccine Immunol (2010) 0.91
Expression of the cholera toxin B subunit (CT-B) in maize seeds and a combined mucosal treatment against cholera and traveler's diarrhea. Plant Cell Rep (2011) 0.91
LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb. Vaccine (2010) 0.89
The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin. Infect Immun (2002) 0.89
AB toxins: a paradigm switch from deadly to desirable. Toxins (Basel) (2010) 0.88
Residues of heat-labile enterotoxin involved in bacterial cell surface binding. J Bacteriol (2009) 0.87
Pathogenesis of human enterovirulent bacteria: lessons from cultured, fully differentiated human colon cancer cell lines. Microbiol Mol Biol Rev (2013) 0.87
High-Resolution Crystal Structures Elucidate the Molecular Basis of Cholera Blood Group Dependence. PLoS Pathog (2016) 0.86
Modified heat-stable toxins (hSTa) of enterotoxigenic Escherichia coli lose toxicity but display antigenicity after being genetically fused to heat-labile toxoid LT(R192G). Toxins (Basel) (2011) 0.83
Polymeric display of immunogenic epitopes from herpes simplex virus and transmissible gastroenteritis virus surface proteins on an enteroadherent fimbria. Clin Diagn Lab Immunol (1999) 0.80
Identification and characterization of intestinal antigen-presenting cells involved in uptake and processing of a nontoxic recombinant chimeric mucosal immunogen based on cholera toxin using imaging flow cytometry. Clin Vaccine Immunol (2013) 0.77
Animal Enterotoxigenic Escherichia coli. Ecosal Plus (2016) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture. Infect Immun (1975) 13.58
Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun (1979) 7.21
Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature (1991) 4.11
Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol (1984) 3.89
Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun (1980) 3.36
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine (1988) 3.00
Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun (1989) 2.74
Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med (1993) 2.62
Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol (1984) 2.51
Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin. J Mol Biol (1993) 2.17
Lactose binding to heat-labile enterotoxin revealed by X-ray crystallography. Nature (1992) 2.08
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A (1997) 2.07
Brefeldin A blocks the response of cultured cells to cholera toxin. Implications for intracellular trafficking in toxin action. J Biol Chem (1993) 1.95
Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J Cell Biol (1995) 1.86
Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc Natl Acad Sci U S A (1996) 1.73
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as an adjuvant. Eur J Immunol (1991) 1.65
Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. J Immunol (1988) 1.60
Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun (1997) 1.54
The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand J Immunol (1991) 1.51
Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis. Mol Microbiol (1991) 1.50
Transcytosis of cholera toxin subunits across model human intestinal epithelia. Proc Natl Acad Sci U S A (1995) 1.46
Galactose-binding site in Escherichia coli heat-labile enterotoxin (LT) and cholera toxin (CT). Mol Microbiol (1994) 1.43
Cholera toxin and its subunits as potential oral adjuvants. Curr Top Microbiol Immunol (1989) 1.43
Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Am J Trop Med Hyg (1994) 1.40
Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol (1994) 1.34
Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect Immun (1995) 1.32
Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine (1994) 1.32
Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol (1993) 1.29
Delineation and comparison of ganglioside-binding epitopes for the toxins of Vibrio cholerae, Escherichia coli, and Clostridium tetani: evidence for overlapping epitopes. Proc Natl Acad Sci U S A (1994) 1.25
Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand J Immunol (1993) 1.21
Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J Immunol (1995) 1.19
Analysis of receptor-binding site in Escherichia coli enterotoxin. J Biol Chem (1985) 1.16
Mucosal priming of T-lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant. Immunology (1991) 1.15
Alterations at the carboxyl terminus change assembly and secretion properties of the B subunit of Escherichia coli heat-labile enterotoxin. J Bacteriol (1987) 1.15
Sealed adult mice: new model for enterotoxin evaluation. Infect Immun (1984) 1.08
Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine (1989) 1.05
Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities of Escherichia coli heat-labile enterotoxin. Infect Immun (1994) 1.05
Reduction in oral immunogenicity of cholera toxin B subunit by N-terminal peptide addition. Infect Immun (1993) 1.01
Role of a potential endoplasmic reticulum retention sequence (RDEL) and the Golgi complex in the cytotonic activity of Escherichia coli heat-labile enterotoxin. Mol Microbiol (1995) 0.98
Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect Immun (1993) 0.98
Development of mucosal protection against the heat-stable enterotoxin (ST) of Escherichia coli by oral immunization with a genetic fusion delivered by a bacterial vector. Infect Immun (1993) 0.92
Receptors for cholera toxin and Escherichia coli heat-labile enterotoxin revisited. Prog Brain Res (1994) 0.91
Cholera toxin as a mucosal adjuvant: III. Antibody responses to nontarget dietary antigens are not increased. Reg Immunol (1991) 0.88
Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun (1979) 7.21
Nonuniform probability of glutamate release at a hippocampal synapse. Science (1993) 4.23
Vibrio cholerae adherence and colonization in experimental cholera: electron microscopic studies. Infect Immun (1976) 4.03
Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin. Infect Immun (1978) 3.95
Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun (1978) 3.80
Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun (1980) 3.36
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Subunit number and arrangement in Escherichia coli heat-labile enterotoxin. Infect Immun (1981) 3.15
Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents. Nature (1990) 3.14
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 2.44
Direct measurement of specific membrane capacitance in neurons. Biophys J (2000) 2.39
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med (1998) 2.20
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev (1992) 2.02
Growth and differentiation of human nasal epithelial cells in culture. Serum-free, hormone-supplemented medium and proteoglycan synthesis. Am Rev Respir Dis (1985) 1.87
Mucosal adjuvants. Vaccine (2005) 1.86
Heteromeric AMPA receptors assemble with a preferred subunit stoichiometry and spatial arrangement. Neuron (2001) 1.72
Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun (1984) 1.70
Immunological and physicochemical characterization of heat-labile enterotoxins isolated from two strains of Escherichia coli. Infect Immun (1982) 1.70
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci U S A (1997) 1.61
Endogenous and exogenous interleukin-12 augment the protective immune response in mice orally challenged with Salmonella dublin. Infect Immun (1996) 1.60
Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol (2001) 1.59
Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine (1998) 1.58
Presynaptic glutamate receptors depress excitatory monosynaptic transmission between mouse hippocampal neurones. J Physiol (1990) 1.52
Does surface chemistry affect thrombogenicity of surface modified polymers? J Biomed Mater Res (2001) 1.45
Septicemia caused by Capnocytophaga in a granulocytopenic patient with glossitis. Arch Intern Med (1980) 1.44
Development of a vaccine of cross-linked heat-stable and heat-labile enterotoxins that protects against Escherichia coli producing either enterotoxin. Infect Immun (1982) 1.44
Effect of a purA mutation on efficacy of Salmonella live-vaccine vectors. Infect Immun (1989) 1.43
Oral immunization of mice with attenuated Salmonella enteritidis containing a recombinant plasmid which codes for production of the B subunit of heat-labile Escherichia coli enterotoxin. Infect Immun (1986) 1.43
Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ (1995) 1.41
Quantal amplitude and quantal variance of strontium-induced asynchronous EPSCs in rat dentate granule neurons. J Physiol (1999) 1.37
Arousal of mucosal secretory immunoglobulin A antitoxin in rats immunized with Escherichia coli heat-labile enterotoxin. Infect Immun (1982) 1.36
Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism. Proc Natl Acad Sci U S A (2000) 1.32
Initiation of multi-leaf collimator conformal radiation therapy. Int J Radiat Oncol Biol Phys (1993) 1.32
Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol (1998) 1.29
Vaccine for enterotoxigenic Escherichia coli based on synthetic heat-stable toxin crossed-linked to the B subunit of heat-labile toxin. J Infect Dis (1983) 1.29
Effect of catecholamines on ion transport in dog tracheal epithelium. J Appl Physiol Respir Environ Exerc Physiol (1979) 1.28
The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine (1999) 1.28
Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun (1994) 1.25
In vivo induction of interleukin-12 mRNA expression after oral immunization with Salmonella dublin or the B subunit of Escherichia coli heat-labile enterotoxin. Infect Immun (1995) 1.24
Photolytic manipulation of [Ca2+]i reveals slow kinetics of potassium channels underlying the afterhyperpolarization in hippocampal pyramidal neurons. J Neurosci (1999) 1.23
Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine (1994) 1.20
Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J Virol (1999) 1.18
Nonuniform distribution of Ca2+ channel subtypes on presynaptic terminals of excitatory synapses in hippocampal cultures. J Neurosci (1997) 1.18
Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine (1993) 1.17
Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. Vaccine (1993) 1.17
Protection against human and porcine enterotoxigenic strains of Escherichia coli in rats immunized with a cross-linked toxoid vaccine. Infect Immun (1983) 1.17
Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers. Infect Immun (1991) 1.15
N- and P/Q-type Ca2+ channels mediate transmitter release with a similar cooperativity at rat hippocampal autapses. J Neurosci (1998) 1.15
Protection in rats immunized with Escherichia coli heat-stable enterotoxin. Infect Immun (1981) 1.13
Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol (1999) 1.13
Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J Immunol (2000) 1.13
Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect Immun (2001) 1.12
Immunization of rats with heat-labile enterotoxin provides uniform protection against heterologous serotypes of enterotoxigenic Escherichia coli. Infect Immun (1981) 1.11
Postsynaptic expression of long-term potentiation in the rat dentate gyrus demonstrated by variance-mean analysis. J Physiol (1999) 1.09
In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae. Infect Immun (1999) 1.08
Cloning and molecular characterization of the B subunit of Escherichia coli heat-labile enterotoxin. Infect Immun (1983) 1.06
Differential production of interleukin-12 mRNA by murine macrophages in response to viable or killed Salmonella spp. Infect Immun (1996) 1.05
Translation rate of human tyrosinase determines its N-linked glycosylation level. J Biol Chem (2000) 1.05
Degradation of trichlorophenols by Alcaligenes eutrophus JMP134. FEMS Microbiol Lett (1995) 1.04
Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. J Virol (2000) 1.03
Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin Vaccine Immunol (2012) 1.02
Intracellular Salmonella dublin induces substantial secretion of the 40-kilodalton subunit of interleukin-12 (IL-12) but minimal secretion of IL-12 as a 70-kilodalton protein in murine macrophages. Infect Immun (1997) 1.02
Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol (2001) 1.02
c-Ki-ras mutations in dysplastic fields and cancers in ulcerative colitis. Gastroenterology (1992) 0.99
Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae. Mucosal Immunol (2011) 0.98
Intracellular tetraethylammonium ions enhance group Ia excitatory post-synaptic potentials evoked in cat motoneurones. J Physiol (1986) 0.97
Proper folding and endoplasmic reticulum to golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine. J Biol Chem (2000) 0.97
Extrauterine pregnancy resulting from early uterine rupture. Obstet Gynecol (1999) 0.97
Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen. Vaccine (1986) 0.97
Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med (2000) 0.97
Chloride uptake into cultured airway epithelial cells from cystic fibrosis patients and normal individuals. Proc Natl Acad Sci U S A (1985) 0.97
Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol (1983) 0.96
VAB-4 combination chemotherapy in the treatment of metastatic testis tumors. Cancer (1981) 0.96
Inactivation of the ampDE operon increases transcription of algD and affects morphology and encystment of Azotobacter vinelandii. J Bacteriol (2000) 0.96
Liposomes as vehicles for vaccines. Prog Clin Biol Res (1980) 0.96
Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G). Vaccine (2000) 0.95
Effects of mutating leucine to threonine in the M2 segment of alpha1 and beta1 subunits of GABAA alpha1beta1 receptors. J Membr Biol (1996) 0.95
Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect Immun (1999) 0.94
Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1. Oncogene (1998) 0.94
Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine (2001) 0.93
Maternal serum alpha-fetoprotein and fetal trisomy-21 in women 35 years and older: implications for alpha-fetoprotein screening programs. Am J Med Genet (1987) 0.93
Development of mucosal protection against the heat-stable enterotoxin (ST) of Escherichia coli by oral immunization with a genetic fusion delivered by a bacterial vector. Infect Immun (1993) 0.92
Growth regulatory proteins that repress differentiation markers in melanocytes also downregulate the transcription factor microphthalmia. J Invest Dermatol (1996) 0.91
Hypolipidaemic drugs are activated to acyl-CoA esters in isolated rat hepatocytes. Detection of drug activation by human liver homogenates and by human platelets. Biochem J (1992) 0.90
Long-term synaptic plasticity in the honeybee. J Neurophysiol (1997) 0.89
Intracellular distribution of heat-labile enterotoxin in a clinical isolate of Escherichia coli. Infect Immun (1985) 0.89
Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine (2002) 0.89
Cell calcium levels of normal and cystic fibrosis nasal epithelium. Pediatr Res (1988) 0.89
Surgical implications of antithrombin III deficiency. Surgery (1981) 0.89
Germ cell tumors (II): VAB II in metastatic testicular cancer. Cancer (1978) 0.87
Contrasting definitive hosts as determinants of the genetic structure in a parasite with complex life cycle along the south-eastern Pacific. Mol Ecol (2015) 0.86
Mucosal T cells induce systemic anergy for oral tolerance. Biochem Biophys Res Commun (1995) 0.85